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Maternal Plasma n-3 and n-6 Polyunsaturated
Fatty Acid Concentrations During Pregnancy
and Subcutaneous Fat Mass in Infancy
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Hans Demmelmair7, Berthold Koletzko7, Vincent W.V. Jaddoe1,2,3, and Romy Gaillard1,2,3
Objective: The associations of maternal plasma n-3 and n-6 polyunsaturated fatty acid (PUFA) concen-
trations during pregnancy with infant subcutaneous fat were examined.
Methods: In a population-based prospective cohort study among 904 mothers and their infants, maternal
plasma n-3 and n-6 PUFA concentrations were measured at midpregnancy. Body mass index, total sub-
cutaneous fat, and central-to-total subcutaneous fat ratio were calculated at 1.5, 6, and 24 months.
Results: Maternal n-3 PUFA levels were not consistently associated with infant body mass index or total
subcutaneous fat. Higher maternal total n-3 PUFA levels, and specifically eicosapentaenoic acid, docosa-
pentaenoic acid, and docosahexaenoic acid, were associated with higher central-to-total subcutaneous
fat ratio at 1.5 months, whereas higher maternal total n-3 PUFA levels were associated with lower
central-to-total subcutaneous fat ratio at 6 months (all P values < 0.05). These associations were not
present at 24 months. Maternal n-6 PUFA levels were not consistently associated with infant subcutane-
ous fat. A higher n-6/n-3 ratio was associated with lower central-to-total subcutaneous fat ratio at 1.5
months only (P value<0.05).
Conclusions: Maternal n-3 PUFA levels during pregnancy may have transient effects on infant subcuta-
neous fat. Further studies are needed to assess the effects of maternal PUFA concentrations on fat mass
development during early infancy.
Obesity (2016) 24, 1759–1766. doi:10.1002/oby.21547
Introduction
Inadequate maternal intake of polyunsaturated fatty acids (PUFA)
during pregnancy may influence the risk of obesity in offspring
(1,2). Several in vitro and animal studies have suggested that PUFA
affect the adipose tissue development during fetal and early post-
natal life (3). Among PUFA, n-3 and n-6 PUFA are of particular
relevance during early life since pathways stimulated by n-6 PUFA
seem to promote, while those stimulated by n-3 PUFA seem to
inhibit, the differentiation of adipocytes (4,5). A U.S. study among
1,250 mother-child pairs showed that higher maternal plasma n-3
PUFA concentrations during pregnancy tended to be associated with
lower total subcutaneous fat mass in children aged 3 years (6). In
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the same study, higher maternal plasma n-6/n-3 PUFA ratio was
associated with higher total subcutaneous fat mass in early child-
hood (6). A Dutch study among 234 mothers and their children
showed that higher maternal plasma concentrations of dihomo-c-
linolenic acid (DGLA), a n-6 PUFA, during pregnancy were associ-
ated with higher total subcutaneous fat mass measured in children
aged 7 years (7). In line with these studies, we have previously
reported that lower maternal n-3 PUFA concentrations and higher
n-6 PUFA concentrations during pregnancy were associated with
higher total body fat and abdominal fat levels at 6 years. Thus far,
not much is known about the influence of maternal plasma PUFA
concentrations during pregnancy on subcutaneous fat mass develop-
ment throughout infancy. Infancy is a period characterized by rapid
growth and subcutaneous fat mass development and is a well-known
critical period for obesity and cardiometabolic diseases later in life
(8,9). By assessing these associations in infancy, further insight into
the early programming effects of maternal PUFA levels on onset
and timing of adiposity in the offspring can be obtained.
Therefore, we examined, in a population-based prospective cohort
study from early pregnancy onwards among 904 mothers and their
infants, the associations of maternal plasma n-3 and n-6 PUFA lev-
els during pregnancy with infant subcutaneous fat mass measures.
Methods
Study design
This study was embedded in the Generation R Study, a population-
based prospective cohort study from early pregnancy onwards
among 9,778 mothers and their children living in Rotterdam, The
Netherlands (10,11). The study protocol was approved by the local
Medical Ethical Committee. Written informed consent was obtained
from parents. Additional detailed assessments of fetal and infant
growth and development were conducted in a subgroup of Dutch
mothers and their children from late pregnancy onwards. Of all
approached women, 80% agreed to participate. A total of 1,205
mothers and their singleton children participated in the subgroup
study, of whom 1,083 mothers had plasma PUFA concentrations
available. Of the group of 1,083 mothers and their children, 904
children had body mass index or skinfold thicknesses measured at
the age of 1.5, 6, or 24 months (flowchart is given in Supporting
Information Figure S1).
Maternal fatty acid status
Maternal nonfasting venous samples were drawn at a median gesta-
tional age of 20.5 weeks (95% range.: 18.6-22.7). As previously
described, EDTA plasma samples were selected and transported to
the Division of Metabolic Diseases and Nutritional Medicine, Dr.
von Hauner Children’s Hospital, University of Munich Medical Cen-
ter to analyze PUFA concentrations (12). After being thawed, the
analysis of plasma glycerophospholipid fatty acids was performed
by a sensitive and precise high-throughput method, suitable in large
epidemiological studies, as previously described (13). Based on find-
ings from previous studies, we selected maternal PUFA for our anal-
yses, which have been associated with the risk of obesity in children
and adults (6,14). Selected maternal PUFA were total n-3 PUFA,
which included a-linolenic acid ((ALA, C18:3n-3) C18:3n-3), eico-
sapentaenoic acid (EPA, C20:5n-3), docosapentaenoic acid (DPA,
C22:5n-3), and docosahexaenoic acid (DHA, C22:6n-3). Total n-6
PUFA included linoleic acid (LA, C18:2n-6), c-linolenic acid (GLA,
C18:3n-6), eicosadienoic acid (EDA, C20:2n-6), (DGLA, C20:3n-6)
DGLA (C20:3n6), arachidonic acid ((ARA, C20:4n-6) C20:4n-6),
and docosatetraenoic acid ((DTA, C22:4n-6) C22:4n-6). PUFA lev-
els were expressed as proportion of total fatty acids present in the
chromatogram (weight percentage, wt %) (15). We also calculated
the ratio of total n-6/n-3 PUFA. We observed similar results when
we used fatty acid concentrations in mg/L instead of percentages
(results not shown).
Body fat measurements during infancy
We measured weight to the nearest gram in naked infants at the age
of 1.5 and 6 months by using an electronic infant scale and at 24
months by using a mechanical personal scale (SECA, Almere, The
Netherlands). Body length at the age of 1.5 and 6 months was meas-
ured in supine position to the nearest millimeter by using a neona-
tometer, and body height at 24 months was measured in standing
position by using a Harpenden stadiometer (Holtain Limited, Dyfed,
UK). Body mass index (kg/m2) was calculated, and we constructed
standard deviation (SD) scores based on our study sample. We
observed similar results when we used age- and sex-adjusted body
mass index SD scores at 24 months based on the World Health
Organization Child Growth Standards (results not shown). We meas-
ured skinfold thicknesses at the age of 1.5, 6, and 24 months on the
left side of the body at the biceps, triceps, suprailiacal, and subscap-
ular area by using a skinfold caliper (Slim Guide, Creative Health
Products) according to standard procedures described in detail previ-
ously. Two measurements were performed at each site and the mean
was used in the analyses. Intraclass correlation coefficient among
observers was 0.88 and between observers was 0.76 (16). As previ-
ously described, we calculated total subcutaneous fat mass from the
sum of all four skinfold thicknesses, central subcutaneous fat mass
from the sum of suprailiacal and subscapular skinfold thicknesses,
and peripheral subcutaneous fat mass from the sum of biceps and
triceps skinfold thicknesses (17). Measurements of body fat quantity
and distribution require appropriate adjustment for body size or total
fat mass, respectively, in order to undertake informative compari-
sons between children and within children over time. To create total
subcutaneous fat mass independent of length or height and central
subcutaneous fat mass independent of total subcutaneous fat mass,
we estimated the optimal adjustment by log-log regression analyses
(18). Based on these analyses, total subcutaneous fat mass was only
weakly correlated with length at 1.5 and 6 months or height at 24
months and was not adjusted for it, whereas a central-to-total subcu-
taneous fat mass ratio was calculated as central divided by total sub-
cutaneous fat mass. The central-to-peripheral subcutaneous fat mass
ratio was calculated as central divided by peripheral subcutaneous
fat mass.
Covariates
We obtained information on maternal age, educational level (low,
medium, high), parity (nulliparous, multiparous), prepregnancy
weight, smoking habits during pregnancy (no/yes), and folic acid
supplement use (no/yes) using self-reported questionnaires during
pregnancy. We measured maternal height at enrolment, and calcu-
lated prepregnancy body mass index (kg/m2). First trimester mater-
nal nutritional information was obtained by food frequency question-
naire (19). Information about pregnancy complications, infants’ sex,
gestational age, and weight at birth was obtained from medical
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records. Gestational weight gain was calculated as the difference
between maternal weight measured at 30 weeks of gestation (95%
range.: 28.5-32.5) and prepregnancy weight. Information about
breastfeeding duration and timing of introduction of solid foods (<3
months, 3-6 months, >6 months) was obtained by questionnaires in
infancy.
Statistical analysis
We assessed the associations of maternal plasma n-3 and n-6 PUFA
levels with infant adiposity measures at 1.5, 6, and 24 months and
the change between these time points using linear regression models.
These regression models were adjusted for gestational age at blood
sampling, maternal age, educational level, parity, prepregnancy body
mass index, maternal total energy intake, smoking habits, weight
gain during pregnancy, folic acid supplement use, gestational diabe-
tes, gestational hypertensive disorders, infants’ sex, gestational age-
adjusted birth weight, breastfeeding duration, and timing of intro-
duction of solid foods. Included covariates were selected based on
their associations with the exposures and outcomes of interest in
previous studies or a change in effect estimate of >10%. We con-
structed SD scores [(observed value2mean)/SD] for all PUFA and
infant adiposity measures to enable comparison of effect estimates.
We have also performed an additional analysis with central-to-
peripheral subcutaneous fat mass ratio using linear regression mod-
els. In addition, we examined the associations of maternal plasma
TABLE 1 Characteristics of mothers and their infants (N5 904)
Value
Maternal characteristics
Age (yr), mean (SD) 31.9 (4.0)
Gestational age at PUFA measures (wk), median (95% range) 20.5 (18.6-22.7)
Prepregnancy body mass index (kg/m2), mean (SD) 23.4 (4.1)
Gestational weight gain (kg), mean (SD) 10.0 (4.5)
Education, n (%) higher education 574 (64.0)
Parity, n (%) nulliparous 555 (61.4)
Total energy intake (kcal), mean (SD) 2,126 (486)
Smoking during pregnancy, n yes (%) 198 (24.1)
Folic acid supplement use, n yes (%) 676 (90.7)
Gestational diabetes, n (%) 10 (1.1)
Gestational hypertensive disorders, n (%) 67 (7.6)
Infant characteristics
Males, n (%) 464 (51.3)
Gestational age at birth (wk), median (95% range) 40.3 (35.8-42.4)
Birth weight (g), mean (SD) 3509 (544)
Breastfeeding duration (months), mean (SD) 4.5 (3.8)
Introduction of solid foods, n (%) >6 months 147 (18.3)
Infant adiposity characteristics
1.5 months
Body mass index (kg/m2), mean (SD) 15.1 (1.4)
Total subcutaneous fat mass (mm), mean (SD) 24.0 (7.3)
Central-to-total subcutaneous fat mass ratio, mean (SD) 0.5 (0.1)
Central-to-peripheral subcutaneous fat mass ratio, mean (SD) 1.0 (0.2)
6 months
Body mass index (kg/m2), mean (SD) 16.8 (1.3)
Total subcutaneous fat mass (mm), mean (SD) 27.0 (6.4)
Central-to-total subcutaneous fat mass ratio, mean (SD) 0.5 (0.1)
Central-to-peripheral subcutaneous fat mass ratio, mean (SD) 0.9 (0.2)
24 months
Body mass index (kg/m2), mean (SD) 15.9 (1.3)
Total subcutaneous fat mass (mm), mean (SD) 27.3 (7.2)
Central-to-total subcutaneous fat mass ratio, mean (SD) 0.4 (0.1)
Central-to-peripheral subcutaneous fat mass ratio, mean (SD) 0.8 (0.2)
Values represent means (SD), medians (95% range), or numbers of subjects (valid %). Body mass index5weight/height2. Total subcutaneous fat mass5biceps1
triceps1 suprailiacal1 subscapular skinfold thicknesses. Central-to-total subcutaneous fat mass ratio5 (suprailiacal1 subscapular skinfold thicknesses)/total subcutane-
ous fat mass.
PUFA, polyunsaturated fatty acids; SD, standard deviation.
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n-3 and n-6 PUFA concentrations during pregnancy with infants
who have overweight and obesity at 24 months (body mass index
above 85th percentile for age and sex) using logistic regression
models. We tested for interaction terms between maternal PUFA
levels and infants’ sex and birth weight in relation to infant adipos-
ity measures at 1.5, 6, and 24 months. Since no statistically signifi-
cant interactions were observed, no further stratified analyses were
performed. We did not adjust the main results for multiple testing
because the main exposures and outcomes were correlated. How-
ever, if we would apply Bonferroni correction, we would consider a
P value of 0.016 as significant (0.05/number of outcomes). In order
to reduce potential bias associated with missing data and to maintain
statistical power, we performed multiple imputations of missing
covariates by generating five independent datasets using the Markov
Chain Monte-Carlo method after which the pooled effect estimates
were calculated. All analyses were performed using Statistical Pack-
age for the Social Sciences version 21.0 for Windows (SPSS Inc,
Chicago, IL).
Results
Subject characteristics
Table 1 shows the maternal and infant characteristics. Mean (SD)
second trimester maternal concentrations of total glycerophospholi-
pid bound n-3 and n-6 PUFA were 111.4 (25.8) mg/L and 592.6
(86.0) mg/L, respectively (Table 2). Nonresponse analyses showed
that as compared with mothers and infants with follow-up measure-
ments, mothers without follow-up measurements were slightly
younger and their infants were breastfed for a shorter period (P <
0.05) (Supporting Information Table S1). Also, mothers included in
the analyses had a higher total n-3 PUFA concentrations compared
with those not included (Supporting Information Table S2). Correla-
tion coefficients between all maternal PUFA concentrations are
shown in Supporting Information Table S3.
Maternal PUFA levels and infant fat mass
Table 3 shows that maternal total n-3 PUFA levels as well as each
n-3 PUFA individually were not consistently associated with infant
body mass index and total subcutaneous fat mass in the adjusted
models. Higher maternal total n-3 PUFA and specifically EPA,
DPA, and DHA levels were associated with higher infant central-to-
total subcutaneous fat mass ratio at 1.5 months (all P values <0.05).
However, only higher maternal total n-3 PUFA levels were associ-
ated with lower infant central-to-total subcutaneous fat mass ratio at
the age of 6 months (P value <0.05). Maternal n-3 PUFA levels
were not associated with infant central-to-total subcutaneous fat
mass ratio at 24 months. Similar results were found in the unad-
justed analyses and are given in Supporting Information Table S4.
Supporting Information Table S5 shows that higher maternal total
n-3 PUFA levels and, specifically, DPA and DHA levels were asso-
ciated with a decrease in central-to-total subcutaneous fat mass ratio
from 1.5 to 24 months, but no associations were found for total sub-
cutaneous fat mass.
Table 4 shows that, in the adjusted models, higher maternal total n-6
PUFA levels were associated with a lower infant total subcutaneous
fat mass at 1.5 months (P value <0.05), but not with infant body
mass index or central-to-total subcutaneous fat mass ratio at any time
points. No consistent associations of individual n-6 PUFA levels with
infant adiposity measures were present at 1.5, 6, or 24 months. Simi-
lar results were found in the unadjusted analyses and are given in
Supporting Information Table S6. Supporting Information Table S7
shows that higher LA levels were associated with an increase in total
subcutaneous fat mass over infancy, and higher ARA levels were
associated with a decrease in body mass index over infancy.
We observed similar results with both maternal n-3 and n-6 PUFA
when we used central-to-peripheral subcutaneous fat mass as com-
pared with the results with central-to-total subcutaneous fat mass
(Supporting Information Tables S8 and S9). Only higher maternal
ARA levels were associated with a lower risk of infant overweight
at 24 months, but no associations were observed for the other n-3
and n-6 PUFAs with the risk of infant overweight (Supporting Infor-
mation Table S10).
Maternal n-6/n-3 PUFA ratio
and infant fat mass
Figure 1 shows that higher maternal n-6/n-3 PUFA ratio was associ-
ated with lower central-to-total subcutaneous fat mass ratio at 1.5
months [difference: 20.10 (95% CI: 20.17 to 20.02) SD per SD
higher maternal n-6/n-3 PUFA ratio], but not with body mass index
and total subcutaneous fat mass. No associations were present for
maternal n-6/n-3 PUFA ratio with infant adiposity measures at 6
and 24 months.
Discussion
In this population-based prospective cohort study, we observed that
higher maternal n-3 PUFA levels were associated with a higher
infant central-to-total subcutaneous fat mass ratio at 1.5 months, but
TABLE 2 Second trimester maternal PUFA concentrations
(N 5904)
Absolute value
(mg/L)
Relative value
(wt %)
Total PUFA 704.1 (96.4) 42.5 (1.6)
Total n-3 PUFA 111.4 (25.8) 6.8 (1.4)
ALA 5.4 (1.6) 0.3 (0.1)
EPA 10.1 (5.3) 0.6 (0.3)
DPA 12.9 (3.9) 0.8 (0.2)
DHA 81.4 (19.4) 5.0 (1.1)
Total n-6 PUFA 592.6 (86.0) 36.3 (2.0)
LA 348.9 (59.6) 21.4 (2.5)
GLA 1.5 (0.7) 0.1 (0.0)
EDA 8.3 (1.7) 0.5 (0.1)
DGLA 63.4 (16.3) 3.9 (0.7)
ARA 155.9 (31.7) 9.5 (1.4)
DTA 6.9 (2.0) 0.4 (0.1)
Values represent means (SD).
ALA, a-linolenic acid; ARA, arachidonic acid; DGLA, dihomo-c-linolenic acid; DHA,
docosahexaenoic acid; DPA, docosapentaenoic acid; DTA, docosatetraenoic acid;
EDA, eicosadienoic acid; EPA, eicosapentaenoic acid; GLA, c-linolenic acid; LA,
linoleic acid; PUFA; polyunsaturated fatty acid.
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with a lower infant central-to-total subcutaneous fat mass ratio at 6
months. Maternal n-3 PUFA levels were not associated with infant
body mass index and total subcutaneous fat mass at any time points.
Higher maternal n-6 PUFA levels were not consistently associated
with subcutaneous fat mass measures during infancy.
Methodological considerations
Major strengths of this study are the population-based prospective
design with detailed information on maternal PUFA concentrations
and infant body fat outcomes. To the best of our knowledge, this is
the largest study to date addressing the association between maternal
PUFA levels during pregnancy with adiposity measures repeatedly
measured in infancy. Of all mothers with available PUFA measure-
ments, 83% (904) of mothers and children participated in the infant
body fat mass measurements. The nonresponse could lead to biased
effect estimates if the associations of interest would differ between
mothers and infants included and not included in the analyses.
Mothers included in the analyses had higher total n-3 PUFA concen-
trations compared with those not included. It is difficult to speculate
if these differences might have influenced our effect estimates. We
measured a large number of maternal PUFA concentrations in
plasma samples once during pregnancy. No information was avail-
able about PUFA concentrations earlier or later in pregnancy.
Nevertheless, PUFAs measured in plasma may reflect a time frame
of dietary intake of approximately 2 weeks and seem to be reasona-
ble indicators for the recent intake (20). We used skinfold thickness
as a measure of subcutaneous fat mass and therefore could not esti-
mate deep fat layers, such as preperitoneal fat. However, during the
first months of life approximately 90% of body fat is located subcu-
taneously and preperitoneal fat mass seems to increase only from
the second year of life onwards (21,22). We studied multiple infant
fat mass outcomes. Since these outcomes are strongly correlated, we
did not adjust our analyses for multiple testing (23). However, a
chance finding cannot be excluded. If we would apply Bonferroni
correction, the associations of total n-3 PUFA levels with central-to-
total fat mass at 6 months, EPA levels with central-to-total fat mass
at 1.5 months, total n-6 PUFA levels with total subcutaneous fat
mass at 1.5 months, and DGLA levels with central-to-total at 6
months are no longer significant. Finally, although we performed an
extensive adjustment for a large number of potential confounders,
residual confounding, due to specific infant diet or physical activity,
might still be an issue.
Interpretation of main findings
An adequate supply of n-3 and n-6 PUFA during pregnancy is
important for optimal fetal and infant growth and development (24).
Rapid weight gain and increased fat mass levels during infancy may
be critical for the development of adiposity in later life (8,9,25,26).
However, thus far no previous study has addressed the associations
of maternal PUFA status during pregnancy with detailed fat mass
measurements throughout infancy.
It has been suggested that lower maternal n-3 PUFA and higher n-6
PUFA concentrations during pregnancy are associated with higher
childhood body mass index (6,7). Fewer studies examined these
associations with body mass index in infancy. A randomized
double-blind controlled trial among 144 mothers and their children
suggested that supplementation by DHA, a n-3 PUFA, during preg-
nancy and lactation reduced body mass index in late infancy (27).
However, an observational study among 244 Dutch mothers and
their breastfed infants showed that n-3 and n-6 PUFA concentrations
in breast milk did not affect body mass index in the first year of life
(28). In this study, we did not observe consistent associations of
maternal n-3 and n-6 PUFA concentrations during pregnancy with
infant body mass index at 1.5, 6, and 24 months.
Body mass index might not be an appropriate measure of fat mass
and provides limited information about body fat distribution (29).
Body fat distribution may be more strongly associated with cardio-
metabolic risk factors than body mass index (30,31). We have previ-
ously shown that maternal lower n-3 PUFA and higher n-6 PUFA
concentrations during pregnancy were associated with higher total
body fat and abdominal fat levels at the age of 6 years. However,
not much is known about maternal PUFA concentrations with off-
spring fat mass outcomes at younger age. Skinfold thickness can be
used to estimate total and regional subcutaneous adiposity (32). A
study among 1,250 mother-child pairs in Massachusetts showed that
higher DHA and EPA, n-3 PUFA concentrations from maternal diet
during pregnancy and measured in cord blood, were associated with
lower total subcutaneous fat mass measured at the age of 3 years
(6). In the same study, higher maternal plasma concentrations of n-6
PUFA and higher ratio of cord plasma n-6/n-3 PUFA were associ-
ated with higher total subcutaneous fat mass at the age of 3 years
(6). The INFAT randomized trial showed that the combination of an
increased n-3 PUFA and a reduced ARA, n-6 PUFA, dietary intake
through supplementation during the perinatal period does not affect
total subcutaneous fat mass during the first year of life (33).
In our study, we observed no consistent associations of maternal n-3
PUFA concentrations with infant total subcutaneous fat mass from
1.5 months to 24 months of age. Higher maternal total n-3 PUFA
and EPA, DPA and DHA concentrations were associated with higher
central-to-total subcutaneous fat mass ratio at 1.5 months. However,
Figure 1 Maternal n-6/n-3 PUFA ratio and infant fat mass measures at 1.5, 6, and
24 months (N5904). Values are regression coefficients (95% confidence interval)
that reflect the difference in SDS of infant body mass index and subcutaneous fat
mass measures at 1.5, 6, and 24 months per SD change in maternal n-6/n-3
PUFA ratio. Body mass index5weight/height2. Total subcutaneous fat mass5
biceps1 triceps1 suprailiacal1 subscapular skinfold thicknesses. Central-to-total
subcutaneous fat mass ratio5 (suprailiacal1 subscapular skinfold thicknesses)/total
subcutaneous fat mass. Models are adjusted for gestational age at blood sampling,
maternal age, educational level, parity, prepregnancy body mass index, maternal
total energy intake, smoking habits and weight gain during pregnancy, folic acid
supplement use, gestational diabetes, gestational hypertensive disorders, infants’
sex, gestational age-adjusted birth weight SD scores, breastfeeding duration, and
timing of introduction of solid foods (for 6 and 24 months). *P< 0.05.
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higher total n-3 PUFA concentrations were associated with lower
infant central-to-total subcutaneous fat mass ratio at 6 months. The
observed associations were not explained by birth weight. Only
higher maternal total n-6 PUFA concentrations were associated with
lower total subcutaneous fat mass at 1.5 months, but not with other
infant adiposity measures or at any other time points. Based on our
findings, it seems that especially maternal n-3 PUFA may stimulate
central subcutaneous fat mass development in early infancy, but this
is a transient effect, which is no longer present in late infancy. The
underlying mechanisms that explain the associations of maternal
PUFA status during pregnancy with offspring fat mass development
in infancy are not clear. It has been suggested that n-3 PUFA avail-
ability during early life leads to increased activation of peroxisome
proliferator-activated receptor (PPAR)-c, which has been associated
with an increased deposition of subcutaneous fat mass, but not vis-
ceral fat mass, in adults (34,35). On the other hand, it has also been
suggested that n-3 PUFA levels in early life inhibit the differentia-
tion of adipocytes, leading to lower levels of fat mass (36). Our
findings might be explained by a greater effect of n-3 PUFA on
PPAR-c and by a less apparent inhibitory effect of n-3 PUFA on the
differentiation of adipocytes in early infancy. Further observational
and experimental studies are needed to explore these detailed under-
lying mechanisms and their potential critical periods.
Conclusion
Maternal n-3 PUFA levels during pregnancy may have transient
effects on infant central subcutaneous fat mass development. Mater-
nal n-6 PUFA levels were not consistently associated with infant
subcutaneous fat mass measures. Further studies are needed to assess
the effects of maternal PUFA levels during pregnancy on detailed
fat mass development throughout early infancy.O
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